Loading…
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $875M | $348M | $264M | $345M | -221.4% | 94.1% | - |
| 2024 | $451M | $13M | $-89M | $-53M | 18.7% | 36.0% | - |
| 2023 | $331M | $-116M | $-227M | $-97M | 49.7% | 22.4% | - |
| 2022 | $271M | $-144M | $-247M | $-163M | 83.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 270.83 | 331.41 | 450.71 | 874.84 |
| Cost Of Revenue | 6.59 | 4.48 | 12.27 | 19.07 |
| Gross Profit | 264.23 | 326.93 | 438.44 | 855.76 |
| Operating Expense | 412.67 | 430.64 | 440.99 | 514.77 |
| Operating Income | -148.44 | -103.71 | -2.54 | 340.99 |
| EBITDA | -143.85 | -116.33 | 12.81 | 347.65 |
| EBIT | -145.29 | -117.99 | 11.56 | 346.26 |
| Pretax Income | -244.38 | -226.23 | -86.95 | 267.39 |
| Tax Provision | 2.73 | 0.31 | 1.93 | 3.53 |
| Net Income | -247.12 | -226.54 | -88.88 | 263.86 |
| Net Income Common Stockholders | -247.12 | -226.54 | -88.88 | 263.86 |
| Total Expenses | 419.26 | 435.12 | 453.25 | 533.85 |
| Interest Expense | 99.09 | 108.24 | 98.52 | 78.87 |
| Interest Income | 5.13 | 15.78 | 14.75 | 10.67 |
| Research And Development | 253.30 | 216.57 | 174.64 | 166.13 |
| Selling General And Administration | 159.37 | 214.07 | 266.35 | 348.65 |
| Normalized EBITDA | -141.87 | -86.28 | 13.45 | 365.14 |
| Normalized Income | -245.55 | -202.79 | -88.37 | 281.17 |
| Basic EPS | -1.33 | -1.18 | -0.43 | 1.26 |
| Diluted EPS | -1.33 | -1.18 | -0.43 | 1.21 |
| Tax Effect Of Unusual Items | -0.42 | -6.31 | -0.13 | -0.17 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.01 |
| Total Unusual Items | -1.98 | -30.06 | -0.64 | -17.48 |
| Total Unusual Items Excluding Goodwill | -1.98 | -30.06 | -0.64 | -17.48 |
| Net Income From Continuing Operation Net Minority Interest | -247.12 | -226.54 | -88.88 | 263.86 |
| Reconciled Depreciation | 1.44 | 1.66 | 1.25 | 1.39 |
| Reconciled Cost Of Revenue | 6.59 | 4.48 | 12.27 | 19.07 |
| Net Interest Income | -93.97 | -92.46 | -83.77 | -68.20 |
| Net Income From Continuing And Discontinued Operation | -247.12 | -226.54 | -88.88 | 263.86 |
| Total Operating Income As Reported | -148.44 | -103.71 | -2.54 | 340.99 |
| Diluted Average Shares | 185.91 | 192.20 | 206.70 | 218.58 |
| Basic Average Shares | 185.91 | 192.20 | 206.70 | 209.89 |
| Diluted NI Availto Com Stockholders | -247.12 | -226.54 | -88.88 | 263.86 |
| Net Income Including Noncontrolling Interests | -247.12 | -226.54 | -88.88 | 263.86 |
| Net Income Continuous Operations | -247.12 | -226.54 | -88.88 | 263.86 |
| Other Income Expense | -1.98 | -30.06 | -0.64 | -5.39 |
| Other Non Operating Income Expenses | 0 | 0 | 0 | 12.09 |
| Special Income Charges | 0 | -29.02 | 0 | -17.33 |
| Other Special Charges | 0 | 29.02 | 0 | 17.33 |
| Gain On Sale Of Security | -1.98 | -1.04 | -0.64 | -0.15 |
| Net Non Operating Interest Income Expense | -93.97 | -92.46 | -83.77 | -68.20 |
| Interest Expense Non Operating | 99.09 | 108.24 | 98.52 | 78.87 |
| Interest Income Non Operating | 5.13 | 15.78 | 14.75 | 10.67 |
| Operating Revenue | 270.83 | 331.41 | 450.71 | 874.84 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals, Inc.this co. | BCRX | $2.3B | 7.43↓ discount | -16.08 | -221.4% | 7.00 |
| IDEAYA Biosciences, Inc. | IDYA | $2.5B | - | 2.41 | -11.1% | -11.82 |
| Guardian Pharmacy Services, Inc. | GRDN | $2.4B | 48.17 | 11.56 | 22.6% | 23.10 |
| Relay Therapeutics, Inc. | RLAY | $2.4B | - | 3.85 | -48.8% | -5.76 |
| Definium Therapeutics, Inc. |
| DFTX |
| $2.2B |
| - |
| 6.09 |
| -55.3% |
| -10.05 |
| Axogen, Inc. | AXGN | $2.2B | - | 15.30 | -12.2% | -1002.00 |
| Adaptive Biotechnologies Corporation | ADPT | $2.2B | - | 9.51 | -26.4% | -52.76 |
| GRAIL, Inc. | GRAL | $2.1B | - | 0.78 | -15.8% | -3.15 |
| Mineralys Therapeutics, Inc. | MLYS | $2.1B | - | 3.22 | -23.9% | -8.50 |
| Peer Median | - | 48.17 | 4.97 | -19.9% | -9.28 | |